Amylin analogues in the treatment of diabetes mellitus: Medicinal chemistry and structural basis of its function

Open Medicinal Chemistry Journal

Volumn 5, Issue SPEC. ISSUE 2, 2011, Pages 78-81

  Adeghate, Ernest ^a   Kalász, Huba ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Amylin; Medicinal chemistry; Pramlintide; Type 1 diabetes

Indexed keywords

AMYLIN; AMYLIN DERIVATIVE; AMYLIN RECEPTOR; GLUCOSE; INSULIN; PRAMLINTIDE;

BINDING SITE; BIOCHEMISTRY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; FOOD INTAKE; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE BINDING; HORMONE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MONOTHERAPY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SKELETAL MUSCLE; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION; VOMITING; WEIGHT REDUCTION;

EID: 80455125812     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501105010078     Document Type: Review

References (27)

1. Lorenzo, A.; Razzaboni, B.; Weir, G. C.; Yankner, B. A., Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature, 1994, 368, (6473), 756-60.
2. Sasahara, K.; Hall, D.; Hamada, D. Effect of lipid type on the binding of lipid vesicles to IAPP amyloid fibrils. Biochemistry, 2010, 49, 3040-3048.
3. Cooper, G. J.; Willis, A. C.; Clark, A.; Turner, R. C.; Sim, R. B.; Reid, K. B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. USA, 1987, 84, (23), 8628-8632.
4. Westermark, P.; Wernstedt, C.; Wilander, E.; Hayden, D. W.; O'Brien, T. D.; Johnson, K. H., Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. USA, 1987, 84, (11), 3881-3885.
5. Nanga, R. P.; Brender, J. R.; Xu, J.; Veglia, G.; Ramamoorthy, A., Structures of rat and human islet amyloid polypeptide IAPP(1-19) in micelles by NMR spectroscopy. Biochemistry, 2008, 47, (48), 12689-12697.
6. Roberts, A. N.; Leighton, B.; Todd, J. A.; Cockburn, D.; Schofield, P. N.; Sutton, R.; Holt, S.; Boyd, Y.; Day, A. J.; Foot, E. A. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc. Natl. Acad. Sci. USA, 1989, 86, (24), 9662-966.
7. Thompson, R.G.; Peterson, J.; Gottlieb, A.; Mullane, J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes, 1997, 46, 632- 636.
8. Heptulla, R.A.; Rodriguez, L.M.; Mason, K.J.; Haymond, M.W. Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. J. Clin. Endocrinol. Metab., 2009, 94 (5), 1608-1611.
9. Hassan, K.; Heptulla, R.A. Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus. Pediatr. Diabetes, 2009, 10 (4), 264-268.
10. Kishiyama, C.M.; Burdick, P.L.; Cobry, E.C.; Gage, V.L.; Messer, L.H.; McFann, K.; Chase, H.P. A pilot trial of pramlintide home usage in adolescents with type 1 diabetes. Pediatrics, 2009, 124, 1344-1347.
11. Dunican, K.C.; Adams, N.M.; Desilets, A.R. The role of pramlintide for weight loss. Ann. Pharmacother., 2010, 44 (3), 538-545.
12. Ryan, G.J.; Jobe, L.J.; Martin, R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin. Ther., 2005, 27(10), 1500-1512.
13. Day, C. Amylin analogue as an antidiabetic agent. Br. J. Diabetes Vasc. Dis., 2005, 5,151-154.
14. Brender, J. R.; Lee, E. L.; Cavitt, M. A.; Gafni, A.; Steel, D. G.; Ramamoorthy, A. Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide. J. Am. Chem. Soc., 2008, 130, (20), 6424-6429.
15. Pittner, R. A.; Albrandt, K.; Beaumont, K.; Gaeta, L. S.; Koda, J. E.; Moore, C. X.; Rittenhouse, J.; Rink, T. J. Molecular physiology of amylin. J. Cell. Biochem., 1994, 55 Suppl, 19-28.
16. Cooper, G.J. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr. Rev., 1994, 15, 163-201.
17. Young, A. Effects of amylin in liver. Adv. Pharmacol., 2005, 52, 229-234
18. Young, A. Inhibition of food intake by amylin. Adv. Pharmacol., 2005, 52, 79-98
19. Fineman, M.; Weyer, C.; Maggs, D.G.; Strobel, S.; Kolterman, O.G: The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm. Metab. Res., 2002, 34, 504-508.
20. Ratner, R. E.; Dickey, R.; Fineman, M.; Maggs, D. G.; Shen, L.; Strobel, S. A.; Weyer, C.; Kolterman, O. G., Amylin replacement with pramlintide as an adjunct to insulin therapy improves longterm glycaemic and weight control in Type 1 diabetes mellitus: a 1- year, randomized controlled trial. Diabet. Med., 2004, 21, (11), 1204-1212.
21. Hollander, P.; Maggs, D.G.; Ruggles, J.A., Fineman, M.; Shen, L.; Kolterman, O.G.; Weyer, C. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes. Res., 2004, 12, 661-668.
22. Hay, D. L.; Christopoulos, G.; Christopoulos, A.; Sexton, P. M., Amylin receptors: molecular composition and pharmacology. Biochem. Soc. Trans., 2004, 32, 865-867.
23. Sexton, P.M.; Albiston, A.; Morfis, M.; Tilakaratne, N. Receptor activity modifying proteins. Cell Signal., 2001, 13, 73-83
24. Poyner, D.R.; Sexton, P.M.; Marshall, I.; Smith, D.M.; Quirion, R.; Born, W.; Muff, R.; Fischer, J.A.; Foord, S.M. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev., 2002, 54, 233-246.
25. Young, A. Amylin receptor pharmacology. Adv. Pharmacol., 2005, 52, 47-65.
26. Bennett, R.G.; Duckworth, W.C.; Hamel, F.G. Degradation of amylin by insulin-degrading enzyme. J. Biol. Chem., 2000, 275, 36621-36625.
27. Shen, Y.; Joachimiak, A.; Rosner, M.R.; Tang, W.J. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature, 2006, 443, 870-874.